Study on the therapeutic effect and molecular mechanism of metronl on diabetic nephropathy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032914

Enrollment

Unknown

Registered

2020-05-15

Start date

2020-05-13

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

normoalbuminuria group:Nil

microalbuminuria group:Nil

macroalbuminuria group:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with type 2 diabetes included in 900 hospitals of the joint service support force, including normal albuminuria group, microalbuminuria group and macroalbuminuria group. 2. According to the diagnostic criteria of the World Health Organization in 1999, the patients were diagnosed as type 2 diabetes. 3. Clinically, through continuous high ACR >= 30 mg / g and / or EGFR < 60 ml / min/ one point seven three A continuous decrease in M2 was identified in patients with diabetic nephropathy.

Exclusion criteria

Exclusion criteria: 1. Patients who use adrenocortical hormone drugs, immunosuppressive drugs or Ras inhibitors; 2. Patients with urinary tract infection; 3. Patients with systemic inflammation; 4. Tumor patients; 5. Patients with cardiovascular diseases; 6. Patients with liver and kidney dysfunction; 7. Patients with COPD and neuroendocrine diseases.

Design outcomes

Primary

Measure	Time frame
serum creatinine;urine albumin creatinine ratio;Metrnl;MCP-1;glycosylated hemoglobin;	—

Countries

China

Contacts

Public ContactPin Chen

The 900th Hospital of Joint Service Support Force

chenpin@21.cn+86 13809550599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026